💸 The Tape

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) responded Tuesday to Curaleaf's stated intention to launch an unsolicited take-over bid — and the response is considerably more interesting than a rejection would have been, because it isn't one.

The board will form a special committee of independent directors to consider the proposal, has made no decision, and told shareholders they need take no action at this time. What Aurora did do, with some precision, was dismantle Curaleaf's characterization of the past seven weeks.

The correction that matters

Boris Jordan's release described repeated attempts to engage, a June 23 letter of intent, a July 7 follow-up, and Aurora's unwillingness to have constructive discussions.

Aurora's version differs on three points, each specific enough to be checkable.

First: the June 23 letter contained no financial terms. Aurora confirms receipt of both letters but states that only the July 7 letter included any proposed financial terms — and even that one did not detail the mix of cash and share consideration. If accurate, that reframes the timeline substantially. A board can't meaningfully engage on a proposal that hasn't specified what it's offering, and the "repeated attempts" become one priced approach, five weeks ago.

Second: Aurora says it did correspond. The company states that its lead independent director corresponded with Curaleaf's CEO, most recently on July 24 — after both letters — communicating that Aurora was focused on executing its business plan over the short to medium term, and explicitly did not discourage ongoing dialogue.

That's the difference between refusing to engage and declining to sell right now. Curaleaf's release, published seventeen days after that correspondence, omitted it entirely.

Third, and sharpest: the cap price is below where the stock recently traded. Aurora notes that the US$5.00 cap on consideration is a lower price than Aurora shares traded as recently as December 18, 2025.

That single sentence does real damage. Curaleaf marketed the cap as generous — an 82% premium, or 197% excluding balance sheet cash. Aurora's reply reframes it as a ceiling set beneath the stock's own eight-month-old trading range. Both statements are true. Which one governs depends entirely on whether you think December 2025 or August 2026 is the fair reference point, and that argument is now the deal.

The strategic counter

Aurora also did something clever with Curaleaf's own logic. Curaleaf built its case on Aurora's EU-GMP cultivation and manufacturing capacity — more than 50 tons annually, including the recently acquired Safari Flower Company.

Aurora's response quotes that back: as noted by Curaleaf, the capacity is highly strategic, and Aurora continues to evaluate additional opportunities to expand it.

Translation: you've told the market our production assets are the scarce thing in global cannabis. We agree. That's precisely why we're not selling them at your price.

The Safari acquisition gets framed as the centerpiece — building on Aurora's global medical platform and leveraging its diversified, scaled network and strong balance sheet. That last phrase is doing work too. Aurora closed its most recent quarter debt-free with US$149.1 million in cash and short-term investments. Curaleaf carries $611.5 million of debt against $107 million of cash.

What happens next for Aurora

Three things, in order.

The special committee forms and retains advisors. Independent directors, independent legal counsel, and — critically — an independent financial advisor to render a formal valuation or fairness opinion. In Canada, an unsolicited bid triggers well-worn machinery, and this is step one.

The clock starts if and only if a formal bid launches. Under Canadian take-over bid rules, a formal bid must remain open a minimum of 105 days, and the board has 15 days from commencement to issue a directors' circular recommending acceptance, rejection, or expressing no opinion with reasons. Aurora has said it does not intend further public comment until disclosure is required or in shareholders' interests — meaning the circular is likely the next substantive word.

The alternatives get tested. A special committee's job isn't only to evaluate the offer in front of it. Aurora's language about other available strategic alternatives is standard, but not empty: expect quiet outreach to determine whether a better bidder exists. Given that every operator in the sector — SNDL, Village Farms, Tilray, Organigram — is racing toward EU-GMP export capacity, Aurora's asset is not one Curaleaf uniquely wants.

What happens next for Curaleaf

Jordan has fewer clean options than the release implied.

Launch the formal bid. The release conspicuously stated no formal take-over bid has commenced with no assurance it will be made. Going formal means filing a take-over bid circular, committing to 105 days, and — because the consideration includes 0.3463 Curaleaf shares — producing a prospectus-level disclosure document about Curaleaf itself. That means a public argument about $611.5 million of debt, a 120 basis point decline in adjusted EBITDA margin, and 3.7% domestic retail growth, conducted while Aurora's advisors are paid to make it.

Raise the price. The obvious response to Aurora's December 18 line is to lift the cap above where the stock traded. Curaleaf's constraint is that US$0.75 per share in cash is already substantial against $107 million of cash on hand. Sweetening in stock dilutes Curaleaf holders further; sweetening in cash requires financing.

Go back to the table. Aurora explicitly did not close the door, twice — in the July 24 correspondence and in Tuesday's release. A negotiated deal with diligence and an NDA is available, and it's the outcome most likely to actually close.

Walk. Least likely. Jordan spent his own earnings week talking about Q4 M&A while already three weeks into this.

The read

Curaleaf's public gambit was designed to pressure a board into engaging. Aurora responded by engaging on the facts — correcting the record, forming a committee, and pricing the cap against its own trading history — without rejecting anything.

That's the harder response to attack. There's no refusal to point at, no shareholder grievance to mobilize, and now a documented correspondence trail that complicates the "they wouldn't talk to us" framing.

Curaleaf has to decide whether it's prepared to spend 105 days and a prospectus arguing its own balance sheet is worth owning. Aurora just made that the question.

📈 Dog Walkers

$ROMJF Solid Q2 Earnings

Rubicon Organics (TSXV: ROMJ) (OTCQX: ROMJF) posted record Q2 net revenue of $18.5 million, up 35% sequentially and 23% year-over-year, while holding the #1 premium licensed producer position in Canada at 6.8% market share.

The brand numbers are the strongest part. 9.7% national share of premium flower, up nearly two points. Wildflower is the #2 topical brand at 30.1% share with the #1 topical SKU in the country. 1964 took Brand of the Year at two industry awards and made its first international commercial launch in the UK medical market.

Profitability moved the other way. Adjusted EBITDA fell 18% to $1.1 million from $1.4 million. Gross profit before fair value adjustments rose just 6% to $5.4 million on a 32% increase in cost of sales — and for the six months, that line is actually down 8%. Headline gross profit of $7.6 million (+30%) leans on $2.2 million of fair value adjustments, up 190%. Worth separating.

CFO Glen Ibbott attributes the squeeze to Cascadia's ramp, which was operationalized on budget and on schedule and contributed roughly $0.5 million of initial revenue. Yields aren't at target yet but are expected there by year-end. Pacifica yields are up 20% per crop. Combined capacity now sits at 15,500 kg annually, with CUMCS and IMC-G.A.P. certifications in hand for international supply.

The constraint is cash: $3.0 million, down from $7.3 million a year ago, against $20.9 million of working capital.

Management says demand consistently exceeds supply and expects margins and EBITDA to ramp through H2. The thesis is sound. The runway is the question.

📺 Trade To Black

TerrAscend Cash Flow Continues While Hemp Ban Debate Escalates | TTB Presented by Flowhub

• TerrAscend's leadership breaks down Q2. Chairman Jason Wild and CEO Ziad Ghanem join to walk through $67.1M in net revenue, modest sequential growth, and a strong 54% gross margin on product mix improvements and operational efficiencies — with adjusted EBITDA of $17.7M and free cash flow positive at $5.7M.

• The balance sheet work is the quarter's real story. An oversubscribed $21.8M convertible debenture financing extended maturities to 2031, retired higher-cost debt, and share repurchases continued — with a special shareholder meeting August 24 to vote on share consolidation as TerrAscend prepares for a potential uplisting.

• Thomas Winstanley on the hemp extension. The President of Edibles.com joins to unpack the federal hemp-THC ban delay, and what operators should actually expect from a regulatory standpoint.

• Washington and the states are moving in opposite directions. While the Senate delays the ban, several states and attorneys general are pushing for stricter enforcement — Thomas explains why the policy environment stays unpredictable as partisan coalitions shift.